ethyl 3-(benzylamino)valerate | 134420-93-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 3-(benzylamino)valerate
• 英文别名: ethyl 3-benzylaminopentanoate；Ethyl 3-(benzylamino)pentanoate
• CAS: 134420-93-2
• 化学式: C₁₄H₂₁NO₂
• 分子量: 235.326
• InChiKey: MBTGZYQVESJFSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(benzylamino)valerate 在 lithium aluminium tetrahydride 、 四丁基碘化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 18.0h， 生成 3-(dibenzylamino)pentan-1-ol
  参考文献：
  名称：

  FUSED CYCLIC COMPOUNDS AND USE THEREOF

  摘要：

  The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.

  公开号：

  WO2024120433A1
• 作为产物：
  描述：

  (cis)-2-pentenoic acid ethyl ester 、 苄胺 以 乙醇 为溶剂， 反应 48.0h， 以40%的产率得到ethyl 3-(benzylamino)valerate
  参考文献：
  名称：

  GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative

  摘要：

  A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1-mu-M. This value is as good as those of the best GABA-uptake inhibitors known today.

  DOI：

  10.1021/jm00112a032

文献信息

• Practical, Highly Enantioselective Chemoenzymatic One-Pot Synthesis of Short-Chain Aliphatic β-Amino Acid Esters
  作者：Harald Gröger、Markus Weiß

  DOI：10.1055/s-0029-1216721

  日期：——

  A practical, highly enantioselective method for the synthesis of short-chain aliphatic beta-amino acid esters was developed starting from prochiral and easily accessible Substrates. This chemoenzymatic approach is based oil a nonenzymatic aza-Michael addition of benzylamine to enoates and subsequent lipase-catalyzed resolution via enantioselective aminolysis. The two reactions are carried out as a

  从前手性和易于获得的底物开始，开发了一种实用的、高度对映选择性的合成短链脂肪族 β-氨基酸酯的方法。这种化学酶促方法是基于油的非酶促氮杂-迈克尔加成苄胺到烯醇并随后通过对映选择性氨解进行脂肪酶催化拆分。这两个反应在无溶剂条件下作为一锅法合成进行，得到了令人满意的 β-氨基酯，收率良好，对映选择性高达 99% ee。
• Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester
  申请人：Miyata Hiroyuki

  公开号：US20050170473A1

  公开（公告）日：2005-08-04

  The present invention discloses a process which comprises selectively hydrolyzing one enantiomer of racemic mixtures of an N-substituted β-amino acid alkyl ester or N-substituted 2-homopipecolic acid ester represented by the formula (I): wherein Ar, R 1 , R 2 , R 3 , R 4 and R 5 are the same as defined in the specification, in the presence of a hydrolase to form an optically active ((R) or (S))-N-substituted-β-amino acid or optically active ((R) or (S))-N-substituted 2-homopipecolic acid represented by the formula (II): and simultaneously to obtain an unreacted optically active ((S) or (R))-N-substituted β-amino acid alkyl ester or unreacted optically active ((S) or (R))-N-substituted 2-homopipecolic acid ester represented by the formula (III): which has a reverse steric absolute configuration to that of the compound represented by the formula (II).

  本发明揭示了一种过程，该过程包括在水解酶的存在下，选择性水解由公式（I）表示的N-取代β-氨基酸烷基酯或N-取代2-同环丙氨酸酯的混合物的一个对映体，其中Ar，R1，R2，R3，R4和R5与说明书中定义的相同，形成一个光学活性的（R）或（S）-N-取代β-氨基酸或光学活性的（R）或（S）-N-取代2-同环丙氨酸，其由公式（II）表示，并同时获得未反应的光学活性的（S）或（R）-N-取代β-氨基酸烷基酯或未反应的光学活性的（S）或（R）-N-取代2-同环丙氨酸酯，其由公式（III）表示，其具有与由公式（II）表示的化合物相反的立体绝对构型。
• PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER
  申请人：Ube Industries, Ltd.

  公开号：EP1493819A1

  公开（公告）日：2005-01-05

  The present invention discloses a process which comprises selectively hydrolyzing one enantiomer of racemic mixtures of an N-substituted β-amino acid alkyl ester or N-substituted 2-homopipecolic acid ester represented by the formula (I):    wherein Ar, R1, R2, R3, R4 and R5 are the same as defined in the specification, in the presence of a hydrolase to form an optically active ((R) or (S))-N-substituted β-amino acid or optically active ((R) or (S))-N-substituted 2-homopipecolic acid represented by the formula (II): and simultaneously to obtain an unreacted optically active ((S) or (R))-N-substituted β-amino acid alkyl ester or unreacted optically active ((S) or (R))-N-substituted 2-homopipecolic acid ester represented by the formula (III): which has a reverse steric absolute configuration to that of the compound represented by the formula (II).

  本发明公开了一种工艺，该工艺包括选择性地水解由式（I）代表的 N-取代β-氨基酸烷基酯或 N-取代 2-高哌啶酸酯的外消旋混合物中的一种对映体： 其中 Ar、R1、R2、R3、R4 和 R5 与说明书中定义的相同、 在水解酶存在下，生成光学活性（(R)或(S)）-N-取代的 β-氨基酸或光学活性（(R)或(S)）-N-取代的由式（II）代表的 2-高代联哌醇酸： 并同时得到未反应的具有光学活性的((S)或(R))-N-取代的 β-氨基酸烷基酯或未反应的具有光学活性的((S)或(R))-N-取代的 2-高代联哌羧酸酯，由式(III)代表： 其立体绝对构型与式 (II) 所代表化合物的立体绝对构型相反。
• US7449325B2
  申请人：——

  公开号：US7449325B2

  公开（公告）日：2008-11-11
• GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative
  作者：Victor N'Goka、Gilbert Schlewer、Jean Michel Linget、Jean Pierre Chambon、Camille Georges Wermuth

  DOI：10.1021/jm00112a032

  日期：1991.8

  A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1-mu-M. This value is as good as those of the best GABA-uptake inhibitors known today.